Characterization of the effects of the vasopressin V2 receptor on sweating, fluid balance, and performance during exercise

Am J Physiol Regul Integr Comp Physiol. 2014 Aug 15;307(4):R366-75. doi: 10.1152/ajpregu.00120.2014. Epub 2014 Jun 18.

Abstract

A regulatory effect of arginine vasopressin (AVP) on sweat water conservation has been hypothesized but not definitively evaluated. AVP-mediated insertion of sweat and salivary gland aquaporin-5 (AQP5) water channels through activation of the vasopressin type 2 receptor (V2R) remains an attractive, yet unexplored, mechanism that could result in a more concentrated sweat with resultant decreased water loss. Ten runners participated in a double-blind randomized control treadmill trial under three separate pharmacological conditions: a placebo, V2R agonist (0.2 mg desmopressin), or V2R antagonist (30 mg tolvaptan). After a familiarization trial, runners ran for 60 min at 60% of peak speed followed by a performance trial to volitional exhaustion. Outcome variables were collected at three exercise time points: baseline, after the steady-state run, and after the performance run. Body weight losses were <2% across all three trials. Significant pharmacological condition effects were noted for urine osmolality [F = 84.98; P < 0.0001] and urine sodium concentration ([Na(+)]) [F = 38.9; P < 0.0001], which verified both pharmacological activation and inhibition of the V2R at the kidney collecting duct. Plasma osmolality and [Na(+)] demonstrated significant exercise (F = 26.0 and F = 11.1; P < 0.0001) and condition (F = 5.1 and F = 3.8; P < 0.05) effects (osmolality and [Na(+)], respectively). No significant exercise or condition effects were noted for either sweat or salivary [Na(+)]. Significant exercise effects were noted for plasma [AVP] (F = 22.3; P < 0.0001), peak core temperature (F = 103.3; P < 0.0001), percent body weight change (F = 6.3; P = 0.02), plasma volume change (F = 21.8; P < 0.0001), and thirst rating (F = 78.2; P < 0.0001). Performance time was not altered between conditions (P = 0.80). In summary, AVP acting at V2R does not appear to regulate water losses from body fluids other than renal excretion during exercise.

Trial registration: ClinicalTrials.gov NCT02084797.

Keywords: V2 antagonist; arginine vasopressin; running; sweat sodium.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antidiuretic Hormone Receptor Antagonists
  • Benzazepines / administration & dosage
  • Biomarkers / blood
  • Biomarkers / urine
  • Deamino Arginine Vasopressin / administration & dosage
  • Double-Blind Method
  • Exercise*
  • Female
  • Hormone Antagonists / administration & dosage
  • Humans
  • Male
  • Middle Aged
  • Neurophysins / antagonists & inhibitors
  • Neurophysins / metabolism*
  • Osmolar Concentration
  • Physical Endurance* / drug effects
  • Plasma Volume
  • Protein Precursors / antagonists & inhibitors
  • Protein Precursors / metabolism*
  • Receptors, Vasopressin / metabolism*
  • Running
  • Signal Transduction
  • Sodium / blood
  • Sodium / urine
  • Sweat / metabolism
  • Sweat Glands / drug effects
  • Sweat Glands / metabolism*
  • Sweating* / drug effects
  • Thirst
  • Time Factors
  • Tolvaptan
  • Vasopressins / antagonists & inhibitors
  • Vasopressins / metabolism*
  • Water-Electrolyte Balance* / drug effects
  • Weight Loss
  • Young Adult

Substances

  • AVP protein, human
  • AVPR2 protein, human
  • Antidiuretic Hormone Receptor Antagonists
  • Benzazepines
  • Biomarkers
  • Hormone Antagonists
  • Neurophysins
  • Protein Precursors
  • Receptors, Vasopressin
  • Vasopressins
  • Tolvaptan
  • Sodium
  • Deamino Arginine Vasopressin

Associated data

  • ClinicalTrials.gov/NCT02084797